These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 33032292

  • 1. The Efficacy of Everolimus for Facial Angiofibromas in Tuberous Sclerosis Complex Patients Treated for Renal Angiomyolipoma/Subependymal Giant Cell Astrocytoma.
    Wei CC, Hsiao YP, Gau SY, Wu YT, Wu CT, Wu MH, Tsai JD.
    Dermatology; 2021; 237(3):444-449. PubMed ID: 33032292
    [Abstract] [Full Text] [Related]

  • 2. The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma.
    Bissler JJ, Franz DN, Frost MD, Belousova E, Bebin EM, Sparagana S, Berkowitz N, Ridolfi A, Kingswood JC.
    Pediatr Nephrol; 2018 Jan; 33(1):101-109. PubMed ID: 28993887
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial.
    Koenig MK, Bell CS, Hebert AA, Roberson J, Samuels JA, Slopis JM, Tate P, Northrup H, TREATMENT Trial Collaborators.
    JAMA Dermatol; 2018 Jul 01; 154(7):773-780. PubMed ID: 29800048
    [Abstract] [Full Text] [Related]

  • 4. Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomized EXIST-1 and EXIST-2 studies.
    Franz DN, Budde K, Kingswood JC, Belousova E, Sparagana S, de Vries PJ, Berkowitz N, Ridolfi A, Bissler JJ.
    J Eur Acad Dermatol Venereol; 2018 Oct 01; 32(10):1796-1803. PubMed ID: 29569806
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Everolimus compliance and persistence among tuberous sclerosis complex patients with renal angiomyolipoma or subependymal giant cell astrocytoma.
    Song X, Said Q, Tran O, Krueger DA, Bissler J.
    Curr Med Res Opin; 2019 Jun 01; 35(6):1103-1110. PubMed ID: 30550347
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex : A Randomized Clinical Trial.
    Wataya-Kaneda M, Nakamura A, Tanaka M, Hayashi M, Matsumoto S, Yamamoto K, Katayama I.
    JAMA Dermatol; 2017 Jan 01; 153(1):39-48. PubMed ID: 27837201
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of everolimus on tuberous sclerosis complex-associated renal angiomyolipoma: A preliminary report.
    Tsai JD, Wei CC, Yang SH, Fan HC, Hsu CC, Tung MC, Tsai ML, Sheu JN.
    Nephrology (Carlton); 2017 Dec 01; 22(12):1017-1022. PubMed ID: 27565896
    [Abstract] [Full Text] [Related]

  • 14. Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial.
    Cai Y, Guo H, Wang W, Li H, Sun H, Shi B, Zhang Y.
    Orphanet J Rare Dis; 2018 Mar 27; 13(1):43. PubMed ID: 29587809
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Fogarasi A, De Waele L, Bartalini G, Jozwiak S, Laforgia N, Verhelst H, Petrak B, Pedespan JM, Witt O, Castellana R, Crippa S, Gislimberti G, Gyorsok Z.
    BMC Neurol; 2016 Aug 08; 16():126. PubMed ID: 27502586
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
    Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S.
    Lancet; 2013 Jan 12; 381(9861):125-32. PubMed ID: 23158522
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex.
    Tanaka M, Wataya-Kaneda M, Nakamura A, Matsumoto S, Katayama I.
    Br J Dermatol; 2013 Dec 12; 169(6):1314-8. PubMed ID: 23909960
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.